	US 11,746,153 B2
	Binding molecules specific for FcγRIIA and uses thereof
Katherine Ann Vousden, Cambridgeshire (GB); Bo Chen, Frederick, MD (US); and Gary Patrick Sims, Potomac, MD (US)
Assigned to Viela Bio, Inc., Deerfield, IL (US)
Filed by VIELA BIO, INC., Deerfield, IL (US)
Filed on Mar. 1, 2022, as Appl. No. 17/684,018.
Application 17/684,018 is a continuation of application No. 16/097,573, granted, now 11,306,145, previously published as PCT/EP2017/060188, filed on Apr. 28, 2017.
Claims priority of provisional application 62/329,627, filed on Apr. 29, 2016.
Claims priority of provisional application 62/349,804, filed on Jun. 14, 2016.
Prior Publication US 2022/0380458 A1, Dec. 1, 2022
Int. Cl. C12Q 1/68 (2018.01); C07K 16/28 (2006.01); A61P 7/00 (2006.01)

CPC C07K 16/283 (2013.01) [A61P 7/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)]

9 Claims

1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a binding molecule that comprises:

(i) a heavy chain variable (VH) region comprising a VH-complementarity determining region (CDR)1 comprising SEQ ID NO: 29, VH-CDR2 comprising SEQ ID NO: 19, and VH-CDR3 comprising SEQ ID NO: 30; and

(ii) a light chain variable (VL) region comprising a VL-CDR1 comprising SEQ ID NO: 22, VL-CDR2 comprising SEQ ID NO: 31, and VL-CDR3 comprising SEQ. ID NO: 32.